Sökning: WFRF:(Docherty Kieran F.) >
Efficacy and Safety...
-
Butt, Jawad H.
(författare)
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide : Insights From the DAPA-HF Trial.
- Artikel/kapitelEngelska2021
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-512644
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-512644URI
-
https://doi.org/10.1161/CIRCHEARTFAILURE.121.008837DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
BACKGROUND: Effective therapies for HFrEF usually reduce NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, and it is important to establish whether new treatments are effective across the range of NT- proBNP. METHODS: We evaluated both these questions in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial. Patients in New York Heart Association functional class II to IV with a left ventricular ejection fraction $<$/=40% and a NT-proBNP level $>$/=600 pg/mL ($>$/=600 ng/L; $>$/=400 pg/mL if hospitalized for HF within the previous 12 months or $>$/=900 pg/mL if atrial fibrillation/flutter) were eligible. The primary outcome was the composite of an episode of worsening HF or cardiovascular death. RESULTS: Of the 4744 randomized patients, 4742 had an available baseline NT-proBNP measurement (median, 1437 pg/mL [interquartile range, 857-2650 pg/mL]). Compared with placebo, treatment with dapagliflozin significantly reduced NT-proBNP from baseline to 8 months (absolute least-squares mean reduction, -303 pg/mL [95% CI, -457 to -150 pg/mL]; geometric mean ratio, 0.92 [95% CI, 0.88-0.96]). Dapagliflozin reduced the risk of worsening HF or cardiovascular death, irrespective of baseline NT-proBNP quartile; the hazard ratio for dapagliflozin versus placebo, from lowest to highest quartile was 0.43 (95% CI, 0.27-0.67), 0.77 (0.56-1.04), 0.78 (0.60-1.01), and 0.78 (0.64-0.95); P for interaction=0.09. Consistent benefits were observed for all-cause mortality. Compared with placebo, dapagliflozin increased the proportion of patients with a meaningful improvement ($>$/=5 points) in Kansas City Cardiomyopathy Questionnaire total symptom score (P for interaction=0.99) and decreased the proportion with a deterioration $>$/=5 points (P for interaction=0.87) across baseline NT-proBNP quartiles. CONCLUSIONS: In patients with HFrEF, dapagliflozin reduced NT-proBNP by 300 pg/mL after 8 months of treatment compared with placebo. In addition, dapagliflozin reduced the risk of worsening HF and death, and improved symptoms, across the spectrum of baseline NT-proBNP levels included in DAPA-HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.
Ämnesord och genrebeteckningar
-
MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Kardiologi hsv//swe
-
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cardiac and Cardiovascular Systems hsv//eng
-
Aged
-
Atrial Fibrillation/drug therapy/physiopathology
-
Benzhydryl Compounds/*adverse effects/*therapeutic use
-
clinical trials
-
Clinical Trials as Topic
-
Glucosides/*adverse effects/*therapeutic use
-
heart failure with reduced ejection fraction
-
Heart Failure/*drug therapy/physiopathology
-
Hospitalization/statistics & numerical data
-
Humans
-
Male
-
Middle Aged
-
Natriuretic Peptide
-
Brain/*therapeutic use
-
natriuretic peptides
-
Peptide Fragments/*therapeutic use
-
sodium-glucose cotransporter 2 inhibitors
-
Stroke Volume/drug effects
-
Ventricular Function
-
Left/drug effects
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Adamson, Carly
(författare)
-
Docherty, Kieran F.
(författare)
-
de Boer, Rudolf A.
(författare)
-
Petrie, Mark C.
(författare)
-
Inzucchi, Silvio E.
(författare)
-
Kosiborod, Mikhail N.
(författare)
-
Maria Langkilde, Anna
(författare)
-
Lindholm, Daniel
(författare)
-
Martinez, Felipe A.
(författare)
-
Bengtsson, Olof
(författare)
-
Schou, Morten
(författare)
-
O’Meara, Eileen
(författare)
-
Ponikowski, Piotr
(författare)
-
Sabatine, Marc S.
(författare)
-
Sjostrand, Mikaela
(författare)
-
Solomon, Scott D.
(författare)
-
Jhund, Pardeep S.
(författare)
-
McMurray, John J. V.
(författare)
-
Kober, Lars
(författare)
Sammanhörande titlar
-
Ingår i:Circulation. Heart failure14:12
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Butt, Jawad H.
-
Adamson, Carly
-
Docherty, Kieran ...
-
de Boer, Rudolf ...
-
Petrie, Mark C.
-
Inzucchi, Silvio ...
-
visa fler...
-
Kosiborod, Mikha ...
-
Maria Langkilde, ...
-
Lindholm, Daniel
-
Martinez, Felipe ...
-
Bengtsson, Olof
-
Schou, Morten
-
O’Meara, Eileen
-
Ponikowski, Piot ...
-
Sabatine, Marc S ...
-
Sjostrand, Mikae ...
-
Solomon, Scott D ...
-
Jhund, Pardeep S ...
-
McMurray, John J ...
-
Kober, Lars
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
- Circulation. Hea ...
- Av lärosätet
-
Uppsala universitet